TY - JOUR
T1 - A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure
T2 - A 12-week, randomized, masked-evaluator multicenter study
AU - Parrish, Richard K.
AU - Palmberg, Paul
AU - Sheu, Wang Pui
PY - 2003/5/1
Y1 - 2003/5/1
N2 - PURPOSE: To Internet Advance publication at ajo.com Feb 13, 2003. compare the intraocular pressure (IOP)-lowering effect and safety of latanoprost, bimatoprost, and travoprost in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). DESIGN: Interventional study. METHODS: This 12-week, randomized, parallel-group study was conducted at 45 US sites. Previously treated patients with OAG or OH and an IOP ≥23 mm Hg in one or both eyes after washout received either latanoprost 0.005%, bimatoprost 0.03%, or travoprost 0.004% once daily in the evening. At baseline and after 6 and 12 weeks of therapy, masked evaluators measured IOP in triplicate at 8:00 AM, 12 noon, 4:00 PM, and 8:00 PM, and masked investigators graded conjunctival hyperemia before the 8:00 AM IOP measurement. The primary efficacy outcome measure was change between baseline and Week 12 in the 8:00 AM IOP (time of peak drug effect). RESULTS: In all, 410 of 411 randomized patients were included in intent-to-treat analyses (latanoprost, 136; bimatoprost, 136; travoprost, 138). Baseline mean 8:00 AM IOP levels were similar (P = .772); by week 12, reductions were observed in all 3 groups (P < .001 for each). Adjusted (ANCOVA) reductions in mean IOP at 8:00 AM were similar (P = .128) as were those at 12 noon, 4:00 PM, and 8:00 PM. Fewer latanoprost-treated patients reported ocular adverse events (P < .001, latanoprost vs bimatoprost), fewer reported hyperemia (P = .001, latanoprost vs bimatoprost), and average hyperemia scores were lower at week 12 (P = .001, latanoprost vs bimatoprost). CONCLUSIONS: Latanoprost, bimatoprost, and travoprost were comparable in their ability to reduce IOP in OAG and OH patients. Latanoprost exhibited greater ocular tolerability.
AB - PURPOSE: To Internet Advance publication at ajo.com Feb 13, 2003. compare the intraocular pressure (IOP)-lowering effect and safety of latanoprost, bimatoprost, and travoprost in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). DESIGN: Interventional study. METHODS: This 12-week, randomized, parallel-group study was conducted at 45 US sites. Previously treated patients with OAG or OH and an IOP ≥23 mm Hg in one or both eyes after washout received either latanoprost 0.005%, bimatoprost 0.03%, or travoprost 0.004% once daily in the evening. At baseline and after 6 and 12 weeks of therapy, masked evaluators measured IOP in triplicate at 8:00 AM, 12 noon, 4:00 PM, and 8:00 PM, and masked investigators graded conjunctival hyperemia before the 8:00 AM IOP measurement. The primary efficacy outcome measure was change between baseline and Week 12 in the 8:00 AM IOP (time of peak drug effect). RESULTS: In all, 410 of 411 randomized patients were included in intent-to-treat analyses (latanoprost, 136; bimatoprost, 136; travoprost, 138). Baseline mean 8:00 AM IOP levels were similar (P = .772); by week 12, reductions were observed in all 3 groups (P < .001 for each). Adjusted (ANCOVA) reductions in mean IOP at 8:00 AM were similar (P = .128) as were those at 12 noon, 4:00 PM, and 8:00 PM. Fewer latanoprost-treated patients reported ocular adverse events (P < .001, latanoprost vs bimatoprost), fewer reported hyperemia (P = .001, latanoprost vs bimatoprost), and average hyperemia scores were lower at week 12 (P = .001, latanoprost vs bimatoprost). CONCLUSIONS: Latanoprost, bimatoprost, and travoprost were comparable in their ability to reduce IOP in OAG and OH patients. Latanoprost exhibited greater ocular tolerability.
UR - http://www.scopus.com/inward/record.url?scp=0037404824&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037404824&partnerID=8YFLogxK
U2 - 10.1016/S0002-9394(03)00098-9
DO - 10.1016/S0002-9394(03)00098-9
M3 - Article
C2 - 12719078
AN - SCOPUS:0037404824
VL - 135
SP - 688
EP - 703
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
SN - 0002-9394
IS - 5
ER -